Thus, we questioned whether the subset of patients with Ewing sarcoma who also harbor germline pathogenic variants in DNA damage repair genes, such as a germline BARD1 mutation, may demonstrate enhanced sensitivity to PARPi/DNA-damaging agent combinations. The gene discussed is BARD1; the disease is Ewing sarcoma.